Pharmac adds Wegovy for weight loss to list for future funding

The decision by Pharmac to include Wegovy in its list of medications suitable for future funding marks a significant step in the agency’s approach to managing obesity-related healthcare costs. The Options For Investment category contains medications that the agency would consider funding if the budget allows, though the specific priority order of these drugs remains private for commercial reasons.

Wegovy, which uses the active ingredient semaglutide, is not currently funded in New Zealand. Individuals seeking the medication must currently pay out-of-pocket, with costs estimated at approximately $400 per month. The inclusion of the drug on the investment list follows a recommendation from Pharmac’s obesity treatments advisory group in February, which suggested the medication be funded with high priority.

Clinical Eligibility and Proposed Thresholds

The advisory group has proposed specific clinical parameters to determine who would qualify for the medication if funding is approved. While the original application requested coverage for adults with a Body Mass Index (BMI) of more than 30, the committee recommended a higher threshold of 35 to align New Zealand with the clinical standards of countries such as Canada, England, and Scotland.

• Dyslipidaemia
• Hypertension
• Diabetes
• Obstructive sleep apnoea
• Established cardiovascular disease

The committee also suggested a tiered approach to eligibility based on the severity of obesity and the economic impact of the treatment. For individuals with a BMI over 50, the recommendation states that no comorbidities would be required for qualification. Conversely, if the cost of funding treatment for those with a BMI of 35 proves to be not cost-effective or cost-prohibitive, the threshold could be raised to a BMI of 40.

To ensure the medication provides clinical value, the recommendation includes a performance-based condition: treatment would cease if a patient does not experience at least a 10 percent reduction in weight after six months of use.

Public Health Context and Economic Impact

The move to include Wegovy comes at a time of significant obesity-related health challenges in New Zealand. Data from the 2024/25 New Zealand Health Survey indicates that an estimated 34 percent of New Zealanders over the age of 15 have a BMI of more than 30. By setting the initial funding threshold at a BMI of 35 rather than 30, Pharmac is attempting to balance broad clinical need with fiscal responsibility.

The decision to categorize Wegovy as an Option For Investment allows the agency to signal intent to clinicians and the public without committing immediate capital. This mechanism is essential for managing the pharmaceutical budget, as the widespread adoption of highly effective weight-loss medications could place substantial pressure on public health spending.

The agency’s decision-making process reflects a broader trend in global healthcare systems where the high cost of GLP-1 receptor agonists is being weighed against the long-term savings associated with reduced complications from diabetes, cardiovascular disease, and other obesity-linked conditions. By linking eligibility to specific comorbidities, Pharmac aims to target the population most likely to see the greatest reduction in secondary health complications.

Future Funding Outlook

The inclusion of Wegovy on the list does not guarantee immediate access for patients. The transition from an investment option to a funded medicine depends on the availability of budget and the agency’s ongoing assessment of cost-effectiveness. Pharmac will continue to monitor the economic implications of obesity treatments as part of its long-term pharmaceutical strategy.

As the agency evaluates these options, the debate over the threshold for BMI and the necessity of comorbidities remains central to the conversation regarding equitable access versus sustainable healthcare spending. For now, the medication remains an out-of-pocket expense for New Zealanders, while the agency prepares for potential future integration into the public health system.

Consult your healthcare provider.